AZD1775–active in phase I clinical study of monotherapy in OvC patients carrying BRCA mutations [215]AZD1775–combination therapy with AZD1775 enhanced carboplatin efficacy in TP53-mutated ovarian tumors in phase II clinical study [216]. The gene discussed is TP53; the disease is ovarian neoplasm.